POST_10th_HTIF
> ATTENDEES
> INVESTORS
> PRESENTERS
> SPONSORS
> SUPPORTERS

20-minute presenters

Darmiyan, Inc.

Darmiyan is a trailblazing biotechnology company that's transforming the field of neurological health by leveraging cutting-edge technology. Incorporated in 2016, the company is focused on pioneering diagnostic solutions for early detection of neurodegenerative diseases, primarily Alzheimer's. Darmiyan's core, novel technology is fully non-invasive and highly-accurate with prognostics information that guides personalized, data-driven disease management. It's scalable and can become widely available around the world.
​
The company's flagship product, BrainSee, revolutionizes the way we approach the screening, monitoring, and diagnosis of Alzheimer’s Disease at the early Mild Cognitive Impairment stage. It uses proprietary algorithms to analyze standard brain MRI scans and identify subtle changes associated with the early stages of neurodegenerative diseases, well before dementia symptoms manifest. The product has earned FDA's Breakthrough Device designation and is on track for approval.

Under the leadership of Dr. Padideh Kamali-Zare, Darmiyan has built a robust intellectual portfolio and collaborated with high-impact academic institutions as well as strategic partners and investors including Eisai and SOMPO. These relationships have collectively enabled the company to execute rigorous technology and product validations.

Darmiyan's team, composed of expert neuroscientists, physicians, and AI specialists, is dedicated to the mission of transforming brain health. They strive to provide patients, caregivers, and physicians with innovative tools that significantly improve the management and prognosis of neurodegenerative diseases.

Darmiyan stands at the forefront of a new era in brain health, marked by early detection and improved patient outcomes. Their pioneering solutions underscore their commitment to tackling some of the world's most pressing health challenges.

www.darmiyan.com

10-minute presenters

AOT AG

AOT AG was founded with the vision to revolutionize orthopedic surgery. Conventional orthopedic saws, drills and burrs were to be replaced by an autonomous robotic platform with a 7-axis robotic arm. CARLO stands for "Cold Ablation Robotic Laser Osteoplasty". CARLO has the following patient benefits:
1.) contact-free (cold laser) orthopedic / neuro surgery
2.) ultra precise (navigation, KUKA robotic arm, laser optics) bone “sculping”
3.) 3D “implant bed” sculping (“reverse 3D printing” allowing for more precise placement of existing implants (e.g. unicondylar knees) and novel types of implant anchorage and shapes (lower profile implants, cementless anchorage etc..)
4.) better bone healing (tissue-sparing cutting of bone with cold laser) during orthopedic surgery.

www.aot.swiss

Calciscon AG

Calciscon is a Swiss life science company with breakthrough products in the field of vascular inflammation and calcification to reduce cardiovascular burden across the entire populations (from apparently healthy adults to the sickest kidney patients).  Calciscon will launch its T50 flagship blood test in partnership with US industry leaders in kidney care to generate €50M+ revenue starting FY 2025.​

calciscon.com/

CardioRenal SAS

CardioRenal has developed the first connected medical device allowing chronic patients to measure their blood potassium at home as easily as diabetic patients measure their glycemia. The device has been validated in a clinical study in Brussels. Commercialisation in Europe will start early 2024.​

cardio-renal.com

Feel Therapeutics

Feel Therapeutics, Inc. is bringing objective data and measurement into the way we diagnose, manage, and care for mental disorders, to realize the vision of Digital Precision Medicine for Mental Health. The company is backed by top-tier investors (Felicis, Anthemis, SOSV) and has partnerships with large pharmaceutical companies to develop novel digital biomarkers and bring digital health solutions to market as standalone digital treatment (DTx) or alongside medications. Feel Therapeutics is headquartered in San Francisco, with additional offices in Europe.

www.feeltherapeutics.com/

GNOMX Corp.

GNOMX Corp. has developed a next-generation epigenetic / AI host-based platform for multiple disease diagnosis. This groundbreaking patent-pending technology was developed by collaborating researchers at the Icahn School of Medicine at Mount Sinai, Princeton University, Yale School of Medicine, and the University of Pittsburgh School of Medicine under a $46 million contract from the Defense Advanced Research Projects Agency (DARPA). The newly developed methods provide significant advantages in accuracy, specificity, and versatility compared to existing approaches, leading to enhanced patient care and reduced treatment costs.

The company’s technology includes artificial intelligence and bioinformatic tools that identify coincident changes in multiple epigenetic data types in blood. This allows GNOMX to develop tests for current or past infections, specific pathogens, antibiotic sensitivity, time of infection, prognosis or post-infectious conditions. New tests can be quickly developed to provide results at a central laboratory or at point-of-care.  

GNOMX will initially focus on Infectious disease diagnostics and is developing differentiated epigenetic diagnostic tests for post-COVID immune dysregulation (Long Covid), acute Lyme disease, and rapid sepsis, indications where no reliable tests currently exist.

In June 2023, GNOMX executed an option with Mount Sinai for a worldwide license to this disruptive technology which provides high-specificity, low cross-reactivity, and compatibility with rapid diagnostic assays that are highly advantageous compared to any existing diagnostic or prognostic technology.

GNOMX is currently raising its first institutional financing of $15 million which will fund the company’s operations for three years. GNOMX is pursuing both equity (venture capital and strategic) and non-dilutive (US government grants and contracts) financing. 


www.gnomx.com

Lifespin GmbH​

Lifespin is building a diagnostics technology platform based on digitized metabolomic data.

We are merging biology, deep data, artificial intelligence, and cloud technologies to enable digital metabolic insights for a new field of precision diagnostics that will improve the gold standard in numerous indications (e.g., prostate cancer) and will bring about new diagnostic products, where none exist today (e.g., in some neurological diseases); precision drug monitoring for clinical, pharmaceutical and research settings; and precision nutrition for diabetes, obesity, dietary and lifestyle interventions.

We are transforming blood samples into digital samples, making it accessible to data science methods. Our AI-enabled technology is highly scalable and built to provide moderate cost diagnostics to both traditional healthcare and new consumer verticals. Lifespin products are software algorithms and do not require advanced chemical reagents.

We have proven performance against legacy methods in clinical chemistry. Our first regulatory approved product, a health testing software-as-a-service (SaaS) for chronic care patients has been launched in May 2023 as a lab developed test (LDT). This will be followed by other tests for the detection of neurological, cancer, and inflammatory diseases. Our cloud-based business model will be built on our proprietary SaaS platform for diagnostics and health information and is globally scalable.

lifespin.health/

neuroClues​

NeuroClues  is a MedTech startup aiming to become the brain’s stethoscope. Our platform leverages eye-tracking technology to provide non-invasive, simple, and robust biomarkers to detect cognitive and neurological disorders, like Parkinson's Disease, 10x faster than current methodologies.​

neuroclues.com/

Yolia Health

Yolia Health’s True Vision Treatment (TVT) is a safe, non-invasive, and repeatable treatment for refractive vision problems like myopia, hyperopia, and even presbyopia. TVT is self-administered by the patient in his or her own home. It employs a combination of customized gas-permeable contact lenses and specially formulated eye drops – which, when used together, safely modify the sphericity of the patient’s cornea.

After only three days of treatment with TVT, patients are freed from using reading glasses and contact lenses for up to 12 months. Patients can “refresh” or update their prescriptions at each subsequent retreatment to ensure they enjoy the best vision possible. One of TVT’s primary advantages over competitors, aside from correcting presbyopia non-invasively, is the ability to correct vision in both eyes without compromising distance vision or depth perception. On the contrary, Yolia's TVT treatment improves near and distance vision, a unique feature no other alternative can provide.

www.yolia.com/

rising medtech/healthtech stars

Active Medical B.V.

Early stage MedTech diagnostic/therapeutic, OxyCam™ - point-of-care vessel imaging solution to visualise and quantify tissue perfusion and blood vessels at the bedside.

Platform technology with clinical and commercial traction. Patents granted.

Founding team have 10 exits including an IPO.

www.activemedical.eu/

Impact Omics BV

Impact Omics is a specialized genomics laboratory in the field of infectious diseases and clinical genomics. Utilizing state-of-the-art genomic technologies integrated into a proprietary workflow, we can detect all clinically relevant pathogens or genomic alterations present in a sample. Results are available within three hours and our pricing strategy sets a new standard in the industry. We offer our services to diagnostic laboratories that wish to expand their current test menu or seek cost-efficient alternatives for their current testing portfolio. We also support biotech companies with their internal pilot clinical studies by rapidly and affordably implementing custom test panels.​

www.impactomics.be

Magnostics

Magnostics is an Irish bionanotech start-up based in Dublin that has developed a blood test for rapid diagnosis of Acute Mesenteric Ischemia (AMI).

There is currently no diagnostic tool for this disease, which affects women 3 times more than men, and has a mortality rate of 60-80%.

Our test could reduce AMI mortality rates by up to 75% while addressing a market estimated at €115M annually.

www.magnostics.com

Moonlight AI GmbH

In the era of personalized Hematology and Oncology, the administration of targeted therapies largely depends on the diagnostics of genomic biomarkers. Moonlight AI aims at accessing this important and predictive genomic information by solely applying computer vision (AI) to scanned images from blood or bone marrow smears of the patients. These smears are collected as part of standard routine diagnostics. The algorithms developed by Moonlight AI will not only provide patients access to diagnostics and, thus, the right treatment, but they will also leverage use of continuous monitoring of patients for therapeutically relevant genomic biomarkers to evaluate response.​

www.moonlight-ai.com/

OptiChroniX GmbH

OptiChroniX: Pioneering Cognitive Wellness through AI-Infused Digital Solutions.

Nestled in Schönenbuch, Switzerland, OptiChroniX is a trailblazer in the digital health sector, specifically targeting the critical area of cognitive wellness as aging populations grow. Built upon the pillars of lifestyle medicine and cutting-edge technology, the company has launched innovative digital wellness tools like myAVOS app, which leverages state-of-the-art AI technology, including large language models from OpenAI and Google's Vertex.

Guided by an interdisciplinary team of experts in neuroscience, lifestyle medicine, and technology, OptiChroniX skillfully marries robust scientific methods with advanced algorithms to provide individualized insights and actionable recommendations for cognitive health enhancement.

Committed to continuous innovation, OptiChroniX integrates the latest research findings and collaborates extensively with healthcare professionals to deliver a user-friendly yet highly effective product experience.

Through a harmonious fusion of digital wellness coaching, lifestyle medicine, and leading AI technologies, OptiChroniX is not merely responding to the challenges of cognitive health; it's rewriting the playbook, empowering individuals to take proactive control of their cognitive well-being.

www.optichronix.com

Qaelon Medical

Founded in 2020, Qaelon Medical is a spin-off from the IHU Strasbourg in France. Our patented technology was born from a real clinical need - avoiding gastrointestinal anastomotic leaks, which often result in devastating complications. We are committed to improve patient outcomes and decrease operative complications after minimally invasive surgery to save lives and costs. Focusing on the user and operational workflow, we offer a full suite of technologies that will become the new gold standard in the detection, prediction, and prevention of anastomosis leaks.

www.qaelonmedical.com/

RetiNov

Based on a fundus photo, blood pressure and a lifestyle questionnaire (nutrition, smoking, alcohol consumption), the MacuTest platform predicts patients’ risk of progressing to the advanced stages of Age-related Macular Degeneration (AMD), using proprietary artificial intelligence algorithms achieving the highest predictive performance in the literature (accuracy equal to 93% at 5 years). This technology has been published in the world’s leading ophthalmology journal, Ophthalmology.

Our objective is to propose personalized monitoring aimed at reducing the risk of visual loss (reinforced ophthalmological follow-up for rapid detection and treatment of advanced forms, lifestyle recommendations, nutritional supplementation, etc.).

Another main objective of the MacuTest platform is also to raise awareness of AMD through popularized information based on the latest scientific advances.

www.macutest.com

Spirecut

Founded in 2020 by Pr Dr Frédéric Schuind in Fribourg, Spirecut SA is a leading Swiss medical device company focused on hand conditions, primarily carpal tunnel syndrome and trigger finger. With one in ten adults facing carpal tunnel syndrome, often requiring invasive surgeries with long recovery times, the need for innovation is clear.

Spirecut's response is the Sono-Instrument®. This single-use medical device allows for percutaneous release using ultrasound imaging, eliminating surgical incisions and ensuring swift patient recovery. Over 1,000 patients have successfully used this solution. Meeting stringent standards, Spirecut is FDA-listed and has forged key distribution agreements. CE mark is expected in early October 2023.

The Sono-Instrument® stands out due to its minimized postoperative pain, lack of surgical scars, quick recovery, suitability for outpatient operations, and reduced need for support staff.

Protecting its innovation, Spirecut holds patents for the Sono-Instrument® in major markets and has registered 'Spirecut' and 'Sono-Instrument®' as trademarks. Supported by the Swiss innovation agency, Spirecut is set to revolutionize percutaneous surgery.

spirecut.com/

VUS Diagnostics

VUS Diagnostics is a genetic focused precision diagnostic company supporting pre-clinical drug development. Our mission is to bring personalised treatment approaches to patients. We do this by designing CRISPR cell based functional assays that address the mechanism underlying the disease biology or drug response. Using such functional assays, we help drug developers identify the patients for whom their precision medicine can reverse disease pathology, or provide more specific cancer treatments. Our main focus is DDR (DNA repair deficient cancers, eg. BRCA cancers) companies because of the market readiness for our solution, and because of our research expertise and personal network to such companies. We have signed the first 2 contracts, the next is pending, and we are busy sending more project proposals to DDR companies. We need an investment to meet this interest, and scale our activities towards a datamodel that allow us eventually be rewarded for helping biotech companies selecting the most relevant patients for their clinical trials.

www.vusdx.com/

Zaya Artificial Intelligence srl

ZayaAI: Revolutionizing Pathology Diagnostics

At the forefront of HealthTech, ZayaAI emerges as an innovator. Joining the 10th Annual HealthTech Investment Forum (#Sachs_HTIF) at Mövenpick Hotel Basel, we introduce our transformative vision: a genuine AI pathology wizard to amplify human experts' capabilities. Our vision? Quicker, remote, more accurate disease diagnoses.

Our Unique Proposition:
Pioneering R&D: Our research reshapes pathology's future. Every AI algorithm, discovery, focuses on transformative outcomes.

Exceptional Team: Comprising bright minds from AI and pathology, our team's expertise is our foundation.

Tangible Impact: We reduce diagnostic errors by 30%, triple pathology diagnostic speed, cut diagnostic delivery by 1-3 days, and decrease lab costs by 30%.

Our Product Suite:
Pathology Laboratory Information System (LIS): Streamlines lab processes, ensuring meticulous tracking.

Telepathology Diagnostic Platform: Overcomes geographical barriers, granting global access to diagnostic expertise.

AI Diagnostics: Specialized tools for Urothelial Carcinoma and Tuberculosis detection, promising unmatched speed and precision.

Join our journey at #Sachs_HTIF. We invite stakeholders to be part of pathology's next evolution. Let's redefine healthcare together.

www.zaya.ai/

VIRTUAL PRESENTERS:

5-MINUTE PRESENTERS:

​Diamante Società Benefit Srl

Diamante Società Benefit srl is a biotech company driven to improve and consolidate the competitiveness and scientific leadership of the European bioindustry in the field of Plant Molecular Farming for autoimmune applications. The current company’s mission is the development of cutting-edge treatment focusing on a solution for Rheumatoid Arthritis (RA).
There is no known cure or preventive measure for this chronic condition; and current treatment primarily revolves around immunosuppression, causing several side effects. The result is a debilitating condition both from a physical and psychological perspective.
Diamante has developed the first worldwide therapy that involves a restoration of the immune system’s ability to recognize a given autoantigen as its own and thus, block its immunological attack.
We have already done two successful PoC on animal models showing complete remission of the disease and we are now moving forward to lead phase 1 clinical studies by the beginning of 2025.

The RA market is a significant and rapidly growing segment in the pharmaceutical industry, driven by the increasing prevalence of the disease worldwide. RA affects approximately 86 million people globally, with an estimated incidence of 20-50 cases per 100,000 population and a prevalence of 1% of the world population. Each year, 1.6-4 million new RA patients are diagnosed, and this number is predicted to double by 2030 due to factors like an aging population, increased awareness of RA, and advancements in medical technology.
We estimated our Total Addressable Market (TAM) based on the global RA market, which is projected to reach €28 billion in 2029, with a compound annual growth rate (CAGR) of 1.0%.

Diamante's business model is built upon a revenue license approach, strategically entering licensing agreements with pharmaceutical companies upon achieving specific stages of development.

www.diamante.tech